CTLA4 and secondary progressive multiple sclerosis: On the other hand, it was shown that the proportion of CTLA-4+ CD4+ T cells in treatment-naive RRMS and SPMS patients was substantially higher than that in healthy controls and that this difference was more pronounced in RRMS patients.